KALV KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks
– Oral KVD900 Primary Endpoint Shows Only 15% Use of Rescue Medication in Patients with Hereditary Angioedema (HAE) –
– KVD900 Generally Safe and Well-Tolerated –
There were no serious adverse events reported in the trial and no patients withdrew due to adverse events.
KALV announced today that it intends to offer and sell 4,500,000 shares of its common stock in an underwritten public offering.